NIH #1R41GM153041-01
Developing novel Type 1 CRISPR tools for gene editing therapy
- Amount
- $293K
- Period
- 2024-02-15 → 2026-01-31
- PIs
- 1
- Est. capacity / PI
- ~0 students
Awarded at GENETOBE INC.
Pluripotent Stem Cells Research · Molecular Biology
1 total · 0 active
NIH #1R41GM153041-01
Awarded at GENETOBE INC.
Student capacity is a rough estimate from remaining award size, split equally among PIs. Actual funding decisions vary.
Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.
SF3B1K700E mutation in human embryonic stem cells causes aberrant expression of immune-related genes
PLoS ONE · 2025-12-17